Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
Eisai and its US ally Merck have discontinued a PIII trial testing the combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with transarterial chemoembolization (TACE) in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC). The partners said on October 29 that…
To read the full story
Related Article
- Lenvima/Keytruda Combo Misses OS Goal in 1st Line GI Cancer Trial
January 27, 2025
- Lenvima/Keytruda Added to TACE Extend PFS in HCC
September 18, 2024
- Lenvima-Keytruda for HCC Misses PIII Primary Goal: Eisai/Merck
September 13, 2022
BUSINESS
- Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026
- Oji Takes Stake in LTL Pharma to Tap LLP Expertise
February 24, 2026
- Hisamitsu Buyout Closed, Drug Maker Set to Go Private in May
February 24, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…